| 货号 | MCA1522G |
| 克隆号 | A6.4.12 |
| 同种亚型 | IgG1 |
| 反应种属 | Human |
| 来源宿主 | Mouse |
| 应用 | C, E, IF, IP, P*, WB |
| 供应商 | Bio-Rad Antibodies |
| 运输条件 | |
| 存放说明 | Store at +4oC or at -20oC if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
HeLa Nuclear Extract probed with Mouse anti Poly (ADP-Ribose) Polymerase (MCA1522G) | |
Western blot analysis of HEK293 whole cell lysate probed with Mouse anti Human poly(ADP-ribose) polymerase-1 antibody (MCA1522G) followed by HRP conjugated Goat anti Mouse IgG, visualized using chemiluminescence | |
Published customer image: Mouse anti poly (ADP-ribose) polymerase 1 antibody, clone A6.4.12 used to immunolocalize PARP-1 expression in normal and Alzheimer's diseased brain by immunohistochemistry on formalin fixed paraffin embedded tissue sections. Image caption: Nucleolar PARP-1 immunoreactivity in AD ranged from absent to dispersed and less intense compared to that of controls. ((a) and (b)) Representative immunostaining with diaminobenzidine (DAB) of human hippocampal pyramidal neurons in CA1 region. (a) Prominent nucleolar staining of PARP-1 (arrows) was seen in most of pyramidal neurons of a control case. (b) The nucleolar staining of PARP-1 ranged from absent (arrowheads) to a more dispersed pattern with less intensity of label (arrows) in pyramidal neurons of an AD case. From: Jianying Zeng, Jenny Libien, Fatima Shaik, Jason Wolk, and A. Iván Hernández, “Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition,” Neural Plasticity, vol. 2016, Article ID 8987928. | |
Published customer image: Mouse anti poly (ADP-ribose) polymerase 1 antibody, clone A6.4.12 used to immunolocalize PARP-1 expression in normal and Alzheimer's diseased brain by immunofluorescence on formalin fixed paraffin embedded tissue sections. Image caption: PARP-1 nucleolar immunoreactivity is altered in hippocampal pyramidal cells in AD brains. Representative confocal microscopy of PARP-1 immunostaining (red) with DAPI nuclear counterstaining (blue) of CA4 hippocampal pyramidal neurons. In controls brains (a–c) a high percentage of pyramidal cell nucleoli have intense and well- delineated PARP-1 staining (arrowheads). In contrast, in AD brains (d–f), the percentage of intensely stained and well-delineated nucleoli is less than in the controls and there is a more dispersed pattern with weak label intensity ((d) and (f), arrow). ((g) and (h)) The percentage of CA1 (g) and CA4 (h) hippocampal pyramidal neurons with PARP-1 positive nucleoli staining was less in AD cases compared to controls. (Control, and for CA1 and CA4, resp.; AD, for both CA1 and CA4; .) Scale bar = 25?μM. From: Jianying Zeng, Jenny Libien, Fatima Shaik, Jason Wolk, and A. Iván Hernández, “Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition,” Neural Plasticity, vol. 2016, Article ID 8987928. | |
Published customer image: Mouse anti poly (ADP-ribose) polymerase 1 antibody, clone A6.4.12 used to immunolocalize PARP-1 expression in normal and Alzheimer's diseased brain by immunohistochemistry on formalin fixed paraffin embedded tissue sections. Image caption: Nucleolar proteins in hippocampal pyramidal cells are altered in AD. ((a)–(h)) Representative figures show colocalization ((d) and (h), yellow) of fibrillarin ((b) and (f), green) and PARP-1 ((c) and (g), red) in the nucleoli of pyramidal neurons. Control cases exhibit high intensity staining (a–d) compared to AD (e–h) (arrowheads). In AD compared to controls, there is a lower percentage of nucleoli that are both PARP-1(+) and fibrillarin(+) ((f)-(g), arrowhead) in CA1 (see Table 2) and CA4 (see Table 3) pyramidal cells and a higher percentage of nucleoli PARP-1(-)/fibrillarin(+) ((f) and (g), arrow) in CA1 (see Table 2) and CA4 (see Table 3), suggesting that different nucleolar proteins are affected in different ways in AD. Scale bar = 20?μm. From: Jianying Zeng, Jenny Libien, Fatima Shaik, Jason Wolk, and A. Iván Hernández, “Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition,” Neural Plasticity, vol. 2016, Article ID 8987928. |
